Medpace Holdings has delivered a strong share price run over the past few years, yet today the valuation picture is split. The Discounted Cash Flow (DCF) intrinsic value estimate points to moderate upside from the current US$581.95 level, while earnings-based multiples screen the stock as expensive and the broader checks look mixed.

• Over the past 5 years Medpace Holdings has returned 229.8%, which puts extra focus on whether recent gains still line up with underlying cash flow potential.
• The business model can support valuation if Medpace Holdings continues to convert revenue into cash flow efficiently, although any setback in contract flow or margins may weigh on what investors are willing to pay.
• The company scores 3 out of 6 on our valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation.

The issue now is whether the DCF-based intrinsic value or the richer earnings multiples provide the more reliable anchor for where Medpace Holdings should trade.

Does Medpace Holdings Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model values Medpace Holdings by estimating the cash it could generate for shareholders in the future and adjusting that back to today. Medpace Holdings currently reports latest twelve month free cash flow of about $706.3 million, and the model assumes that these cash flows continue to grow over time rather than decline.

Based on these assumptions, the DCF model points to an intrinsic value of about $656 per share, compared with the current share price around $581.95. That gap implies the stock trades at an 11.2% discount to the model’s estimate of what its cash flows are worth. The key question for you as an investor is whether Medpace Holdings can keep converting revenue into cash flow at similar levels, because the valuation is quite sensitive to any change in that trend.

On this cash flow view, Medpace Holdings stock appears undervalued relative to its estimated intrinsic value.

Our Discounted Cash Flow (DCF) analysis suggests Medpace Holdings is undervalued by 11.2%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Is Medpace Holdings Getting Expensive on Earnings?

The P/E ratio is a useful way to see what you are paying today for each dollar of Medpace Holdings earnings. On this measure, the stock currently trades on a P/E of about 33.0x.

That sits below the Life Sciences industry average of roughly 37.8x and also below the peer group average of about 48.0x. However, a more tailored fair P/E multiple for Medpace Holdings, which factors in its margins, growth profile, size and risk, is estimated at about 21.5x. The current 33.0x is well above that level. Even though the stock does not look stretched against some peers, it still prices in a richer earnings multiple than this model would suggest.

On this earnings multiple view, Medpace Holdings stock screens as overvalued relative to its fair P/E benchmark.

The Medpace Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Medpace Holdings sit between the DCF result and the richer P/E multiple, and turn that valuation gap into clear, testable assumptions about Medpace Holdings' future growth, margins and earnings on the Community page. Where a single ratio or model gives you one figure, these narratives spell out the future that figure depends on, so you can track over time whether those conditions actually play out.

The community is split on Medpace Holdings, with one side arguing the current price underestimates its earnings power while the other sees rich expectations already baked in.

Bull case: 16% undervalued

"Medpace's ongoing investments in proprietary technology and digital trial infrastructure uniquely position the company to benefit from the growing adoption of decentralized and complex clinical trials, supporting margin expansion and creating potential for higher-than-expected long-term earnings growth..."

Bear case: 46% overvalued

"Decreasing backlog, now down nearly 2% year-over-year, and elevated backlog conversion rates signal that Medpace may be pulling forward future revenue at the expense of longer-term growth, increasing the risk of a significant revenue deceleration and lower earnings visibility in 2026 and beyond..."

Do you think there's more to the story for Medpace Holdings? Head over to our Community to see what others are saying!

The Bottom Line

For Medpace Holdings, the Discounted Cash Flow (DCF) intrinsic value suggests some upside, while the earnings multiple points to an overvalued stock on a P/E basis. That split reflects different focuses. The intrinsic value view leans on cash flow generation and funding needs, while the market multiple view is tied to growth expectations and how peers are priced. With broader checks sitting in the middle rather than clearly cheap or clearly expensive, the key issue from here is whether Medpace Holdings can sustain cash conversion and earnings quality strongly enough to justify the current multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.